Mandate

Vinge advises Xspray Pharma in connection with its listing on Nasdaq Stockholm

Vinge advises Xspray Pharma AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm. The prospectus was published on 23 March 2020 and the trading on Nasdaq Stockholm commenced on 27 March 2020.

Xspray Pharma is a product development company that develops improved and generic versions of marketed drugs, primarily protein kinase inhibitors for the treatment of cancer. Xspray has multiple product candidates in clinical development.

Vinge’s team has primarily consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Joel Magnusson, Maria Schultzberg, Stojan Arnerstål and Henrik Wastenson.

Related

Vinge advises Infranity in connection with the acquisition of Nordic Re-Finance AB

Vinge has advised Infranity, a private equity firm specializing in infrastructure investments, in connection with its acquisition of a majority stake in Nordic Re-Finance AB, a Scandinavian locomotives lessor. The acquisition brings ambitious development plans for Nordic Re-Finance AB, including expansion into new geographical areas.
January 20, 2025

Vinge advises Platzer in conjunction with the sale of a school property in Gothenburg

Vinge has advised Platzer Fastigheter AB in connection with the sale of a school property situated in Södra Änggården, Gothenburg. The property, which was sold as a corporate transaction, has a value of SEK 552 million. The sale is part of Platzer's strategy to develop and optimise its property portfolio.
January 17, 2025

Vinge advises Qben Infra in connection with issuance of senior, unsecured bonds and early redemption

Vinge has advised Qben Infra AB in connection with its issuance of senior, unsecured bonds in an amount of SEK 500,000,000 (within a framework of SEK 600,000,000) and the parallel early redemption by its subsidiary ININ Group AS in respect of its previously issued senior secured bonds due 2027.
January 16, 2025